Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Other Working Capital Changes: 2023-2025

Historic Other Working Capital Changes for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $1.6 million.

  • Zenas BioPharma's Other Working Capital Changes rose 189.44% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 587.77%. This contributed to the annual value of $7.7 million for FY2024, which is 129.95% up from last year.
  • As of Q3 2025, Zenas BioPharma's Other Working Capital Changes stood at $1.6 million, which was up 238.61% from -$1.2 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Other Working Capital Changes high stood at $8.2 million for Q4 2024, and its period low was -$1.8 million during Q3 2024.
  • Over the past 3 years, Zenas BioPharma's median Other Working Capital Changes value was -$401,000 (recorded in 2025), while the average stood at $891,875.
  • Per our database at Business Quant, Zenas BioPharma's Other Working Capital Changes surged by 698.97% in 2024 and then crashed by 137.23% in 2025.
  • Quarterly analysis of 3 years shows Zenas BioPharma's Other Working Capital Changes stood at -$1.4 million in 2023, then spiked by 698.97% to $8.2 million in 2024, then spiked by 189.44% to $1.6 million in 2025.
  • Its Other Working Capital Changes stands at $1.6 million for Q3 2025, versus -$1.2 million for Q2 2025 and $353,000 for Q1 2025.